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It is well established that surgery, especially
gastrointestinal cancer surgery, in nonbleeding
cirrhotic patients carries a high risk of mortality and
morbidity. Esophagogastrectomy for carcinoma in
cirrhotic patients has been mentioned only occa-
sionally in the literature. Our aim was to review
literature results in esophageal and gastric cancer
surgery, to identify cirrhotic patients who will beneﬁt
from surgery, and to give to surgeons technical
speciﬁcities of such surgery.
ESOPHAGEAL CANCER
The surgical management of esophageal cancer in
cirrhotic patients is associated with signiﬁcant
morbidity and mortality, with rates of 83–87% and
17–30%, respectively.
1–5 These ﬁgures are comparable
to the morbidity and mortality rates in noncirrhotic
patients, which are of the order of 30–40% and below
5%, respectively.
6,7
The most common causes of morbidity and mor-
tality following surgical treatment of esophageal
cancer are pulmonary complications and ﬁstulas.
These complications are not signiﬁcantly more fre-
quent in cirrhotic patients.
3,4 Pulmonary complica-
tions do not result in increased mortality different
from that observed for other infectious complications
(ﬁstulas, sepsis) which are responsible for postoper-
ative demise in about two-thirds of patients.
3,4 The
most common complication in cirrhotic patients fol-
lowing esophageal surgery is ascitic effusion, which is
the cause of death in about one-third of patients.
3
This ascites is associated with the interruption of the
esophageal and periesophageal vascular collaterals
and with extensive lymph node dissection. Heavy
perioperative blood loss increases the mortality.
4
Postoperative hepatic insufﬁciency is fatal in just less
than one patient in two. Speciﬁc and almost inevita-
bly fatal postoperative complications are hepatorenal
syndrome and portal thrombosis.
3
The preoperative factors predictive ofpostoperative
mortality in cirrhotic patients proposed for esopha-
gectomy are (1) the degree of hepatic insuﬃciency re-
ﬂectedbytheChildscore,aChildscoreofBorCbeing
associated with unacceptable postoperative mortality,
(2)aprothrombinvalue £ 60%,and(3)acutealcoholic
hepatitis
1–3 and weight loss exceeding 15% of body
weight.
4 The approach (with or without thoracotomy
or thoracic or cervical anastomosis) has not been
shown to inﬂuence postoperative mortality.
3
In terms of survival, the prognosis of cirrhotic
patients appears more severe than for noncirrhotic
patients at the same stage (21% vs 42% 3-year
survival, respectively, P = .051).
4 Nevertheless, after
excluding postoperative deaths, there does not appear
to be any prognostic difference between cirrhotic and
noncirrhotic patients,
4,5 in particular regarding mor-
tality beyond the postoperative period in relation to a
complication of cirrhosis. The suggested explanations
are suppression of the collaterals secondary to
esophagectomy and alcoholic withdrawal secondary
to the relative postesophagectomy loss of appetite.
4,5
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680GASTRIC CANCER
Gastric surgery excluding bleeding in cirrhotic
patients is associated with slightly increased mor-
bidity and mortality, with mean rates of 40% and
10%, respectively, for gastric cancer.
8,9 These ﬁgures
are comparable to the morbidity and mortality rates
in noncirrhotic patients, which are of the order of
20% and below 3%, respectively.
10
In cirrhotic patients operated on for gastric cancer,
the most common postoperative complications are
ascites (14%), wound infections (11%), and hepatic
encephalopathy. The hemorrhagic and infectious
complications are slightly higher with rates of about
4.3% and 9%, respectively. The risk of anatomotic
leakage does not appear to be increased.
11
The preoperative factors predictive of postopera-
tive mortality in cirrhotic patients proposed for gas-
trectomy are (1) the degree of hepatic insuﬃciency
reﬂected by the Child score, a Child score of B or C
being associated with unacceptable postoperative
mortality, (2) preoperative liver function test abnor-
malities, especially an aspartate transaminase (ASAT)
rate > 40 UI/L, (3) a preoperative transfusion indi-
cating a hemorrhagic event,
12 (4) an aspiration
drain,
11,13 and (5) and extensive dissection especially
of the hepatoduodenal ligament, promoting the onset
of considerable postoperative ascites.
9,11,14 The extent
of the gastrectomy does not seem to inﬂuence the
surgical sequelae.
11
With regard to survival, the prognosis of cirrhotic
patients appears to be worse than that for noncirrh-
otic patients at the same stage. In contrast to
esophageal cancer, after excluding postoperative
mortality, the main causes of decease are related to
the development of the cirrhosis such as the hepatic
insuﬃciency, hemorrhagic complications, and hepatic
cancer.
9,15
CONCLUSION
Because cirrhotic patients with esogastric cancer
have the same chance of cure as do noncirrhotic pa-
tients when postoperative complications are managed
well with low mortality rate, the mere presence of
cirrhosis should not be considered a contraindication
for curative surgery. Esophagectomy and gastrectomy
for cancer in cirrhotic patients should only be
considered for very carefully selected patients, even if
the selection appears to have to be less strict for
gastric cancer, i.e., Child A patient, normal preoper-
ative liver function tests, and no previous history of
edematoascitic decompensation. The speciﬁc surgical
aspects are (1) perfect hemostasis, (2) avoidance of
postoperative drainage for gastric cancer whereas it
seems to be recommended for esophageal cancer, (3)
prevention of infections, (4) water and sodium
restriction and compensation of electrolyte losses, and
(5) nutritional support. For locally advanced squa-
mous cell carcinoma of the esophagus, this potentially
morbid surgery is to be balanced against deﬁnitive
chemoradiation that allowed 2-year survival rates
similar to chemoradiation followed by surgery.
16
Whether for cancer of the stomach or esophagus,
the best candidates for surgery are patients without
clinical and biological symptoms in whom the
cirrhosis is discovered by chance during surgery.
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